secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001193125-25-047174
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics appoints Stelios Papadopoulos to Board of Directors
---------------------------------------------------------------------

- Board expanded from five to six directors; Papadopoulos appointed Class I director, term through 2027 annual meeting.
- Papadopoulos co-founded Exelixis, served as Chairman of Biogen (2014-2023), and has extensive biotech investment banking background.
- Appointed to Audit Committee and Compensation Committee, effective March 1, 2025.
- Non-employee director compensation updated: $45,000 base retainer, initial 90,000 stock options grant, annual 45,000 options.
- Entered standard indemnification agreement covering expenses for actions arising from director service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000119312525047174/0001193125-25-047174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000119312525047174/d844381d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-047174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer